RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Ombow, Here's a likely timetable. Most of these are based on Dr. Stoll's comments at the recent Montreal Conf presentation, with my guesses in (parentheses) -

1) Early '07 - Will need to raise some money (likely in the $10-12 mil range via a shelf offering).

2) End of Feb/early March - the go/no go decision on CX-717, based on the new tox study results which Cortex should be getting and analyzing over the next month or so.

3) Q1-07 - The first non-Ampakine in-license.

4) Early Q2 - Cortex gets the draft report for the CX-701 tox studies.

5) Mid Q2 - (FDA decision on dose liberalization, if Cortex decides to seek one).

6) 2007 - Global Neurodegenerative/High Impacts BP deal (I'm figuring by Summer, though could possibly be sooner).

7) Early Q3-07 - CX-701 enters human Phase 1.

8) Q3-07 - AD PET scan with CX-717 completed.

9) End of 2007 - Lead high impact should go into toxicology.

10) Early 2008 - Can initiate Phase 2 trials with CX-701.


Also, sometime in 2007 the Org-24448 Schizo monotherapy results could be published.